Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

BACKGROUND: New therapies are urgently needed in melanoma particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. METHODS: Drug screening, IC50 determinations as well as synergy assays were detected by the MTT assay. Apoptosis using Annexin V and 7AAD staining wa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Liu, Wei, Stachura, Paweł, Xu, Haifeng C., Umesh Ganesh, Nikkitha, Cox, Fiona, Wang, Ruifeng, Lang, Karl S., Gopalakrishnan, Jay, Häussinger, Dieter, Homey, Bernhard, Lang, Philipp A., Pandyra, Aleksandra A.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035645/
https://ncbi.nlm.nih.gov/pubmed/32085796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-1539-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars